DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Loibl S, O‘Shaughnessy J, Untch M. et al.
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone
to standard neoadjuvant chemotherapy in triple-negative breast cancer
(BrighTNess): a randomised, phase 3 trial.
Lancet Oncol 2018;
19: 497-509
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.